Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apixaban versus warfarin for venous thromboembolism prophylaxis in adult primary nephrotic syndrome
ACTRN12619001193167Phase 4Not yet recruiting
- Sponsor
- Royal Brisbane and Women's Hospital
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of apixaban and warfarin in nephrotic syndrome (NS) (2 arms), sponsored by Royal Brisbane and Women's Hospital. Primary endpoints: Efficacy of anticoagulant and Safety of anticoagulant. Planned start Feb 2020; status: not yet recruiting.
02
Drugs
apixabanwarfarin
03
Conditions
nephrotic syndrome (NS)
Beyond the preview
Go deeper on ACTRN12619001193167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12619001193167.